Data Sheet (Cat.No.T6999)

TargetMol

Teneligliptin hydrobromide

Chemical Properties



CAS No. : 906093-29-6

Formula: C22H30N6OS·5/2BrH

Molecular Weight: 628.86

Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Actual storage temperature shall be subject to the COA.

Biological Description

Description	Teneligliptin hydrobromide (MP-513 (hydrobromide)) is a novel, potent, and long-lasting dipeptidyl peptidase-4 inhibitor; competitively inhibited human plasma, rat plasma, and human recombinant DPP-4 in vitro, with IC50 values of approximately 1 nM.
Targets(IC50)	Apoptosis,NF-κB,Proteasome,NOD-like Receptor (NLR),DPP-4,AMPK, Immunology/Inflammation related,Interleukin,JNK,p38 MAPK,ROS

Solubility Information

Solubility	DMSO: 50 mg/mL (79.51 mM),Sonication is recommended. Ethanol: 17 mg/mL (27.03 mM),Sonication is recommended. H2O: 100 mg/mL (159.02 mM),Sonication is recommended. (< 1 mg/ml refers to the product slightly soluble or insoluble)
In vivo Formulation	10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (3.18 mM),Sonication is recommended. *Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.*

Preparing Stock Solutions

	1mg	5mg	10mg
1 mM	1.5902 mL	7.9509 mL	15.9018 mL
5 mM	0.318 mL	1.5902 mL	3.1804 mL
10 mM	0.159 mL	0.7951 mL	1.5902 mL
50 mM	0.0318 mL	0.159 mL	0.318 mL

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. Please use it as soon as possible.

Note: The dilution table applies only to solid products. For liquid products, please calculate the stock solution based on the stated concentration and/or density.

Reference

Kishimoto M, et al. Diabetes Metab Syndr Obes. 2013, 6:187-95.
Sameshima A, et al. J Endocrinol. 2015, 227(1):25-36.
Ideta T, et al. Int J Mol Sci. 16(12):29207-18.
Pujadas G, et al. Endocrine. 2016, [Epub ahead of print].